Skip to main content


ABBV-552 is an SV2A modulator which is being evaluated to target nerve terminals to enhance synaptic efficiency. The mechanism is being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders.

Type of Molecule

Small Molecule



Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Alzheimer's Disease n/a
Phase 1